Get the Stockscreener App
19.27
17.72%
-4.15
Enliven Therapeutics Inc stock is traded at $19.27, with a volume of 1.68M.
It is down -17.72% in the last 24 hours and down -1.73% over the past month.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
See More
Previous Close:
$23.42
Open:
$23.25
24h Volume:
1.68M
Relative Volume:
3.42
Market Cap:
$1.14B
Revenue:
-
Net Income/Loss:
$-85.21M
P/E Ratio:
-10.20
EPS:
-1.89
Net Cash Flow:
$-68.53M
1W Performance:
-9.95%
1M Performance:
-1.73%
6M Performance:
-6.05%
1Y Performance:
-30.26%
1-Day Range:
$18.33
$23.31
1-Week Range:
$18.33
$24.64
52-Week Range:
$13.30
$29.79
Enliven Therapeutics Inc Stock (ELVN) Company Profile
Name
Enliven Therapeutics Inc
Sector
Industry
Phone
720-647-8519
Address
6200 LOOKOUT ROAD, BOULDER
Compare ELVN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ELVN
Enliven Therapeutics Inc
|
19.27 | 1.39B | 0 | -85.21M | -68.53M | -1.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.56 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.26 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.85 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
183.87 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Enliven Therapeutics Inc Stock (ELVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-16-25 | Initiated | Goldman | Buy |
| Dec-13-24 | Initiated | BTIG Research | Buy |
| Sep-09-24 | Initiated | H.C. Wainwright | Buy |
| Jun-11-24 | Initiated | Robert W. Baird | Outperform |
| Apr-09-24 | Initiated | Mizuho | Buy |
| Mar-29-23 | Initiated | Jefferies | Buy |
View All
Enliven Therapeutics Inc Stock (ELVN) Latest News
Enliven Therapeutics Inc. stock daily chart insightsMarket Risk Analysis & Reliable Price Action Trade Plans - newser.com
Enliven Therapeutics showcases promising results for ELVN-001 in CML trial - Traders Union
Enliven (NASDAQ: ELVN) presents ELVN-001 CML data at ASH 2025 with >1 log transcript declines - Stock Titan
Can Enliven Therapeutics Inc. stock deliver strong Q4 earnings2025 Market Overview & Long-Term Growth Stock Strategies - newser.com
Is Enliven Therapeutics Inc. stock a contrarian buy2025 Short Interest & Fast Moving Trade Plans - newser.com
Using data filters to optimize entry into Enliven Therapeutics Inc.Oil Prices & Community Supported Trade Ideas - newser.com
Is Enliven Therapeutics Inc. stock positioned well for digital economy2025 Geopolitical Influence & Verified Momentum Stock Alerts - newser.com
Applying sector rotation models to Enliven Therapeutics Inc.Weekly Profit Summary & Daily Risk Controlled Trade Plans - newser.com
Why Enliven Therapeutics Inc. stock appeals to dividend seekers2025 Short Interest & Growth Oriented Trading Recommendations - newser.com
Enliven Therapeutics Inc. recovery potential after sell offEarnings Overview Report & Weekly Watchlist of Top Performers - newser.com
Is Enliven Therapeutics Inc. stock a safe haven assetWeekly Earnings Recap & Fast Entry Momentum Alerts - newser.com
Is Enliven Therapeutics Inc. stock cheap compared to fundamentalsInsider Selling & Free Expert Verified Stock Movement Alerts - newser.com
Automated trading signals detected on Enliven Therapeutics Inc.Portfolio Value Report & Safe Swing Trade Setups - newser.com
Real time breakdown of Enliven Therapeutics Inc. stock performanceWeekly Trade Review & Entry Point Confirmation Signals - newser.com
Is Enliven Therapeutics Inc a good long term investmentFederal Reserve Announcements & Build Wealth With Zero-Cost Tools - earlytimes.in
Enliven Therapeutics (ELVN): Evaluating Valuation Following Phase 1 ELVN-001 Update for Resistant Leukemia - Sahm
Will Enliven Therapeutics Inc. stock outperform tech sector in 2025Quarterly Portfolio Summary & Verified Technical Trade Signals - fcp.pa.gov.br
Will Enliven Therapeutics Inc. stock rally after Fed decisionsMarket Risk Summary & Real-Time Volume Surge Alerts - fcp.pa.gov.br
Enliven Therapeutics Advances in CML Treatment with ELVN-001 Study - TipRanks
Enliven Therapeutics Inc Stock (ELVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Enliven Therapeutics Inc Stock (ELVN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Kintz Samuel | PRESIDENT AND CEO |
Oct 17 '25 |
Sale |
21.33 |
12,500 |
266,654 |
902,892 |
0.27%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):